Quarterly report [Sections 13 or 15(d)]

Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail)

v3.26.1
Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Outstanding and nonvested as of December 31, 2025, Number of Shares [1]     4,566    
Granted, Number of Shares [2]     1,457    
Vested, Number of Shares     (1,867)    
Forfeited, Number of Shares [3]     (114)    
Outstanding and nonvested as of June 30, 2026, Number of Shares [1] 4,042   4,042    
Expected to vest as of June 30, 2026, Number of Shares [4] 3,589   3,589    
Outstanding and nonvested as of December 31, 2025, Weighted Average Grant Date Fair Value Per Share [1]     $ 9.67    
Granted, Weighted Average Grant Date Fair Value Per Share [2]     18.81    
Vested, Weighted Average Grant Date Fair Value Per Share     10.91    
Forfeited, Weighted Average Grant Date Fair Value Per Share [3]     11.8    
Outstanding and nonvested as of June 30, 2026, Weighted Average Grant Date Fair Value Per Share [1] $ 12.34   12.34    
Expected to vest as of June 30, 2026, Weighted Average Grant Date Fair Value Per Share [4] $ 12.09   $ 12.09    
Stock Appreciation Rights (SARs)          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of Awards Outstanding, Beginning Balance [5]     13,249    
Granted, Number of Awards     1,004    
Exercised, Number of Awards     (380)    
Forfeited, Number of Awards [6]     (422)    
Number of Awards Outstanding, Ending Balance [5] 13,451   13,451    
Number of Awards Exercisable, Ending Balance [7] 7,021   7,021    
Number of Awards Vested and expected to vest, Ending Balance [7] 9,980   9,980    
Weighted Average Exercise Price Per Award Outstanding, Beginning Balance [5]     $ 11.07    
Granted, Weighted Average Exercise Price Per Award     18.52    
Exercised, Weighted Average Exercise Price Per Award     9.49    
Forfeited, Weighted Average Exercise Price Per Award [6]     29.39    
Weighted Average Exercise Price Per Award Outstanding, Ending Balance [5] $ 11.1   11.1    
Exercisable, Weighted Average Exercise Price Per Award, Ending Balance [7] 12.29   12.29    
Weighted Average Exercise Price Per Award, Vested and expected to vest, Ending Balance [7] $ 12.12   $ 12.12    
Weighted Average Remaining Contractual Term Outstanding [5]     6 years 10 months 24 days 7 years  
Exercisable Weighted Average Remaining Contractual Term [7]     7 years    
Weighted Average Remaining Contractual Term, Vested and expected to vest [7]     7 years 7 months 6 days    
Aggregate Intrinsic Value Outstanding [5],[8] $ 46.5   $ 46.5   $ 45.4
Exercisable, Aggregate Intrinsic Value [7],[8] 19.3   19.3    
Aggregate Intrinsic Value, Vested and expected to vest [7],[8] $ 29.0   $ 29.0    
Granted, Weighted Average Grant Date Fair Value Per Share $ 7.96 $ 3.88 $ 10.13 $ 4.14  
[1] Includes 2.8 million and 1.6 million performance-based restricted stock units as of June 30, 2026 and December 31, 2025, respectively, which represents the maximum amount that can vest.
[2] Includes 1.3 million performance-based restricted stock units.
[3] Includes less than 0.1 million performance-based restricted stock units.
[4] Includes 2.4 million performance-based restricted stock units.
[5] Includes 3.7 million and 3.9 million performance condition SARs as of June 30, 2026 and December 31, 2025, respectively.
[6] Includes 0.2 million performance condition SARs.
[7] Includes 0.3 million performance condition SARs.
[8] The intrinsic value is the amount by which the current market value of the underlying stock exceeds the exercise price of the stock awards.